[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100429529":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":28,"locations":34,"responsibleParty":53,"collaborators":55,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":10,"studyType":72,"phases":10,"briefSummary":73,"conditions":74,"keywords":79,"overallStatus":37,"whyStopped":10,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":91},{"fullName":5,"class":6},"Richmond Pharmacology Limited","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with MASLD",null,"Patients with known MASLD",[13],"Diagnostic Test: Bioimpedence Vector Analysis",{"label":15,"type":10,"description":16,"interventionNames":17},"Healthy volunteers","Patients without any known health issues",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"DIAGNOSTIC_TEST","Bioimpedence Vector Analysis","Bioimpedence vector analysis",[15,9],[25],{"name":26,"affiliation":5,"role":27},"Jorg Taubel, MD","PRINCIPAL_INVESTIGATOR",[29],{"name":30,"role":31,"phone":32,"phoneExt":10,"email":33},"James Rickard","CONTACT","+44 (0)20 7042 5800","grants@richmondresearchinstitute.org",[35],{"facility":36,"status":37,"city":38,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Richmond Pharmacology Ltd. 1a Newcomen St, London Bridge","RECRUITING","London","SE1 1YR","United Kingdom","UK",{"type":43,"coordinates":44},"Point",[45,46],-0.12574,51.50853,{"lat":46,"lon":45},[49,51],{"name":30,"role":31,"phone":10,"phoneExt":10,"email":50},"j.rickard@richmondpharmacology.com",{"name":52,"role":27,"phone":10,"phoneExt":10,"email":10},"Jorg Taubel, MD FFPM",{"type":54,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[56],{"name":5,"class":6},"100429529","development-of-a-non-invasive-screening-tool-to-predict-metabolic-dysfunction-associated-steatotic-liver-disease-100429529",false,"NCT04873258","Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease","Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Volunteers on Clinical Trials Utilising Machine-learning and Bioimpedance Vector Analysis","MASLD","Inclusion Criteria:\n\n1. Male or female volunteers aged ≥18 to ≤80 years at the date of signing the informed consent.\n2. Willingness and ability to provide written, personally signed, and dated informed consent, in accordance with the latest ICH Good Clinical Practice (GCP) Guidelines and applicable regulations.\n3. An understanding, ability and willingness to fully comply with project procedures and restrictions.\n\nFor PART B only:\n\n1\\. With a known history of MASLD as evidenced either of:\n\n1. GP diagnosis on HCF\n2. Documented Fibroscan or liver US demonstrating MASLD\n\nExclusion Criteria:\n\n1. Known alcoholic liver disease, history of cirrhosis of any other cause (metabolic, viral hepatitis or other)\n2. Any other significant previous liver pathology (liver malignancy, portal hypertension, infiltrative liver disease)\n3. Alcohol consumption \\>30 units per week\n4. An Implanted cardiac devices",true,"ALL","18 Years","80 Years",{"count":70,"type":71},2000,"ESTIMATED","OBSERVATIONAL","A generic screening study to establish structural and\u002For functional baselines of specific organs.",[75,76,63,77,78],"Healthy","Fatty Liver","MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease","Obesity and Obesity-related Medical Conditions",[80,63],"Fatty liver","2025-07-18",{"date":83,"type":84},"2025-07-23","ACTUAL",{"date":86,"type":84},"2019-09-27",{"date":88,"type":71},"2027-12-31",{"name":90,"class":6},"Richmond Research Institute",1]